Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous, Charlotte Green, Thomas Jackson, Michael Ferguson, Janet M. Lord (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review


Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. Here, we review the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. There is growing evidence that targeting ageing mechanisms can reduce or delay age-related diseases in animal models, and the first reports of clinical trials are now appearing. Although these trials currently focus on repurposed drugs, we propose several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations.

Original languageEnglish
Number of pages13
JournalDrug Discovery Today
Publication statusE-pub ahead of print - 20 Jun 2020


Dive into the research topics of 'Treating age-related multimorbidity: the drug discovery challenge'. Together they form a unique fingerprint.

Cite this